For most people the daily aching and the brown ankle stains are what gets noticed first; the ropes themselves are just the tip of it. Modern endovenous ablation — heat or medical glue — closes the broken vein in one office visit and keeps things quiet for years. The catch: roughly one in four come back within five years because the underlying disease recruits a new vein, and the old "wear stockings for six months and see" advice has been formally dropped from the major guidelines. If your legs ache, swell, itch, or the skin around your ankles is changing colour, you've moved past the cosmetic conversation.
Leg veins move blood uphill against gravity using one-way flap valves and the squeeze of the calf muscle every time you take a step. When one of those flaps fails to close — usually in the great saphenous vein that runs from groin to ankle — blood slides back down on standing, the vein swells with the extra pressure, and the next valve below gets stretched open. The cycle propagates downward. By the time the surface vein is visibly ropy, the pressure has been climbing for years.
That pressure is what does the real damage. Capillaries leak fluid into the ankle (the daily swelling), red blood cells leak out and break down into iron pigment that stains the skin permanently brown, and a low-grade inflammatory state turns the lower-leg fat woody and tight — the "upside-down champagne bottle" look clinicians describe in advanced cases Caggiati 2008. Closing the broken vein — surgically, with heat, or with glue — breaks the cycle. The blood reroutes through deeper, competent veins; the surface vein scars down and disappears over months.
What we know works
Treating refluxing leg veins is one of the better-studied things in vascular medicine. Four interventions have multicentre randomised trials with 5-year follow-up: open surgery (high ligation and stripping), endovenous laser ablation, radiofrequency ablation, and ultrasound-guided foam sclerotherapy. The big UK trial randomised 798 people with primary varicose veins to laser, foam, or surgery and tracked them out to five years. Laser and surgery both beat foam on disease-specific quality of life; laser had fewer complications than surgery and ended up the most cost-effective option Brittenden et al. 2019. The Danish trial of 500 patients added radiofrequency to the comparison and found roughly equivalent durability for laser, radiofrequency, and surgery — and a much higher recanalisation rate for foam at five years (about 32% vs. 6%) Lawaetz et al. 2017.
For people who've already crossed into venous ulcers, the evidence is sharper still. Add early ablation of the refluxing surface vein to standard compression and the ulcer heals faster and stays gone longer — a clean win in the EVRA trial Gohel et al. 2018. Stripping the same vein cut 12-month ulcer recurrence from 28% to 12% in the older ESCHAR trial; at four years, recurrence was 31% with surgery added vs. 56% with compression alone Barwell et al. 2004 Gohel et al. 2007.
The piece of the evidence base that surprises most people is what compression stockings can't do. They don't cure varicose veins, they don't shrink them, and they don't modify the underlying valve disease. They relieve symptoms while you wear them and they're mandatory for ulcer healing and prevention of ulcer recurrence — but NICE explicitly recommends against using compression as treatment for varicose veins unless an intervention isn't possible NICE CG168.
What "leave it alone" actually looks like
Most people with mild varicose veins never reach the bad end of this disease — but enough do that the typical reader should know what they're declining. Roughly a quarter of adults have visible varicose veins by population surveys; about one in six has chronic venous insufficiency severe enough to cause persistent ankle swelling or skin changes; about one in 150 has an active or healed venous ulcer at any given time Bonn Vein Study 2003.
The progression isn't dramatic. In your forties the legs feel heavier at the end of a long day on your feet — you start sitting down sooner, you stop wearing dresses that show the calves, sock-elastic leaves deeper grooves than it used to. By the fifties, ankles puff by 6pm and don't fully come down overnight, the skin around the medial ankle starts to look slightly tanned even in winter, and standing in line at a checkout becomes the part of the errand you dread. By the sixties, that tan is the brown of permanent haemosiderin staining, the skin gets tight and shiny and the calf takes on the inverted-bottle shape, and a knock against a coffee table that would have been a bruise turns into a slow-healing wound. Once an ulcer forms, the average healing time is months, the recurrence rate without intervention is over 50% at four years, and the daily life it imposes — bandaging, dressings, weekly clinic visits — is the reason vascular surgeons call ulcer prevention the whole point of the field Gohel et al. 2007.
The other parts of the cost are quieter. The night cramps that wake you at 3am, the unsettled crawling sensation in your calves that makes the last hour of the day impossible to sit through — both correlate strongly with surface venous reflux and ease after the underlying vein is treated Pyne et al. 2022. Varicose veins also modestly raise the risk of deep-vein thrombosis; the size of the causal link is smaller than older observational studies claimed, but it's there Chang et al. 2018. None of this kills the typical reader. It just slowly costs them their evenings, their ankles, and a decade or two later their skin.
The modern pathway
The first step is the same for everyone the major guidelines actually want treated — duplex ultrasound. A trained sonographer maps which veins are refluxing, in which direction, and from where; treatment is planned from that map. The visible bulges on the skin are a poor guide to what's actually broken underneath, and treating tributaries without closing the main refluxing trunk feeding them is the most reliable way to guarantee recurrence.
With reflux confirmed, the recommended first-line treatment is endovenous thermal ablation of the refluxing trunk — laser or radiofrequency. The clinician threads a thin fibre into the vein, numbs the tissue around it with a saline-anaesthetic mix (tumescent anaesthesia), then heats the vein from the inside as the fibre is withdrawn. The vein scars closed; blood reroutes through deeper, competent veins. The procedure runs 30–60 minutes, uses no general anaesthetic, and most people walk in and out of the office the same morning and return to work in 1–3 days. Visible tributary veins on the surface are treated at the same session or in a staged follow-up — by tiny stab incisions (phlebectomy) or by injection of a foam or liquid sclerosant that scars them shut.
If thermal ablation isn't a good fit — vein too close to skin or nerve, patient preference, or anatomical limitations — the second-line options are non-thermal: medical-grade cyanoacrylate glue (VenaSeal, non-inferior to radiofrequency at three years in the VeClose trial Morrison et al. 2015) or ultrasound-guided foam sclerotherapy. Surgical stripping is still done, particularly when the anatomy doesn't suit endovenous techniques, but its share of the workload has dropped sharply since the guidelines moved.
What to unlearn
"It's just cosmetic." The single most common misread, repeated in many primary-care offices because that's how the disease was taught for forty years. Visible varicose veins are evidence of valve failure; the question isn't whether to do something about them, it's whether the legs have already started talking to you. Once they're aching at the end of the day, swelling, itching, or changing colour, the cosmetic framing is wrong.
"Try compression stockings for six months first." Still embedded in many regional referral policies, but explicitly contradicted by the national guidelines: compression doesn't fix varicose veins, and delaying intervention while you trial it is unnecessary for a symptomatic person NICE CG168. A UK audit found ~58% of commissioning policies were still restricting access this way; if you're being told to wait six months on stockings before a specialist will see you, that's a policy issue, not a clinical one.
"It's a women's problem." Women are far more likely to seek treatment and to report symptoms, but the Edinburgh Vein Study found visible trunk varices in 40% of men vs. 32% of women in a random population sample — the population disease burden is comparable or higher in men, who just present later Evans et al. 1999.
"Recurrence means the procedure failed." All four major modalities recur over five years — the Kaplan–Meier estimates from the Danish trial run roughly 19% for radiofrequency, 39% for laser, 32% for foam, and 35% for stripping Lawaetz et al. 2017. Recurrence usually reflects the underlying disease recruiting a new refluxing segment, not technical failure of the original procedure. A second ablation a decade later is normal, not a sign something went wrong.
"Sclerotherapy of spider veins is the answer." If the spider veins are being fed by an unmapped refluxing truncal vein, they come straight back. A duplex scan before any sclerotherapy work is the cheap insurance against repeatedly paying to treat the symptom of a problem nobody looked for.
When to wait
Worth knowing: all ablation techniques carry a small (roughly 1–3%) risk of procedural deep-vein thrombosis. The procedural risk is real but well below the long-term DVT risk varicose veins themselves carry untreated. Most clinics screen with a brief post-procedure duplex.
Cost, access, recovery
In the UK, varicose-vein referral and treatment are covered under the NHS for anyone meeting the NICE referral criteria; in practice, regional commissioning policies can slow access for the lower-severity cases, and a private endovenous ablation runs roughly £1,500–£3,000 per leg. In the US, most insurers cover endovenous ablation when reflux is documented on duplex and symptoms are present; out-of-pocket pricing on the private market is roughly $2,000–$5,000 per leg. Foam sclerotherapy for spider veins typically runs $300–$600 per session and is usually not covered (it's classed as cosmetic when the truncal system is competent).
The procedure itself is anticlimactic. Local tumescent anaesthesia, a small entry point at the knee or calf, the catheter passes up the vein under ultrasound guidance, and the vein is closed over the next few minutes as the catheter withdraws. People walk out, drive home (or are driven home if any sedation was used), and resume desk work the next day. Tightness and a tender cord along the treated vein last 2–4 weeks; bruising fades over the same period. Compression stockings are worn during the day for 1–2 weeks per most institutional protocols — though the optimal duration isn't well-established and varies by clinic.
Class-2 graduated compression stockings cost roughly $50–$120 per pair and need replacing every 3–6 months as the elastic fatigues. Adherence is the hard part — surveys consistently find less than half of patients prescribed daily compression actually wear them daily.
What changes once it's treated
Within the first week, the legs feel lighter. The end-of-day ache you'd stopped noticing because you'd had it for years is suddenly absent; you sit down in the evening and realise you haven't been thinking about your calves. The bruising and tightness along the treated vein are noticeable for a fortnight, then fade. People notice the bruise; they don't notice the vein is gone yet — that comes later.
By month three, the visible ropy varicosities have flattened and faded; the surface vein has scarred down and is being reabsorbed. Tributary spider veins treated by sclerotherapy in the same session are mostly gone. Disease-specific quality of life — measured on the Aberdeen questionnaire that captures pain, swelling, itching, skin changes, and activity interference — improves substantially and the improvement holds out to five years Brittenden et al. 2019. The Singapore cyanoacrylate registry saw Aberdeen scores drop from 17 to 5 and severity scores from 5 to 1 inside three months — that's the size of the felt change in the early window.
By the end of the first year, the ankles aren't swelling by 6pm anymore. Restless legs and the 3am cramps that came along with the venous disease are usually quieter or gone Pyne et al. 2022. People around you stop asking why your ankles look bruised; the slightly tanned look around the medial ankle starts to lighten — though long-standing haemosiderin staining can take years to fully clear, and the worst-stained skin never quite returns to baseline. For someone who came in with a venous ulcer, the timeline is different and the stakes are higher: ulcers healed faster on average with early ablation in the EVRA trial, and people got back more than four weeks of ulcer-free time in the first post-treatment year — measured in trial endpoints, lived as "I can wear shoes again, I can sleep without the bandage" Gohel et al. 2018.
At the five- to ten-year mark, roughly one in four to one in three will develop recurrent varicose veins as the underlying disease recruits a new refluxing segment. Recurrence is treatable — usually with another ablation or sclerotherapy session — and isn't a sign the first procedure failed. The decade-long arc is steady comfort with occasional retouches, not one permanent fix.
How the options compare
- Endovenous thermal ablation (laser or radiofrequency). First-line for refluxing truncal veins per NICE and the SVS/AVF/AVLS. Durable, with 5-year clinical recurrence ~19–39% across the major trials. Laser and radiofrequency are close to interchangeable; radiofrequency has slightly less post-procedure pain in head-to-head trials, laser has slightly less post-treatment pigmentation.
- Cyanoacrylate closure (VenaSeal). Medical-grade glue delivered through the same kind of catheter — no heat, no tumescent anaesthetic, so the procedure is faster and less uncomfortable. Non-inferior to radiofrequency at three years Morrison et al. 2015; long-term durability past five years is less certain because the extension cohort was small. Real but uncommon risk: hypersensitivity reaction to the glue.
- Ultrasound-guided foam sclerotherapy. Cheap, office-based, no incisions, and excellent for tributary varicosities. As a stand-alone treatment for the main refluxing trunk, it has the highest 5-year recanalisation rate (~32% in the Danish trial) and the lowest disease-specific QoL gain Brittenden et al. 2019. Best used as an adjunct or for anatomy unsuitable for thermal ablation.
- High ligation and stripping. The traditional operation — durable, but requires general or spinal anaesthesia and a longer recovery. Largely displaced by endovenous techniques but still used when anatomy demands it.
- Daily compression stockings without intervention. Symptom control, not cure. Right answer when intervention isn't suitable, when you're waiting for a procedure, or postpartum during the wait-and-see window. Mandatory after a venous ulcer — class 2 (20–30 mmHg) reduces recurrence by roughly half compared with class 1.
- Lifestyle. Walking activates the calf pump and helps symptoms; the flip side is that holding one position for hours — whether sitting at a desk or standing in one spot — lets blood pool in the legs and brings the aching on, so getting up to move every half hour and rotating between sitting and standing beats either extreme. Sustained leg elevation does the same; weight loss in the overweight reduces the intra-abdominal pressure driving the disease. None of these reverse established varicose veins, but they're free and they help.
Who needs to pay attention sooner
Two groups warrant earlier consideration than the average reader.
Older readers with any visible varicosities should look in the mirror at their ankles. The brown staining around the medial ankle, the slightly shiny tightness of the skin, any eczema-like patch that comes and goes — these are the late C4 signs that mean the disease is no longer C2, and they're the bridge to ulceration. A venous ulcer in your sixties is a months-long, painful, recurring problem that's much easier prevented than healed.
Pregnancy reliably surfaces varicose veins; about 15% of pregnancies do so, mostly in the second trimester, and roughly half of women who develop them keep some degree of disease afterward. The clinical move is to wear compression during pregnancy if symptomatic, hold off on procedures until at least three months postpartum, and wait until you're done having children before electing definitive treatment — recurrence climbs with each subsequent pregnancy.
Genetics is the single biggest individual risk factor. If both parents had visible varicose veins, your risk is roughly six times the population baseline; if one parent did, it's still elevated. Occupational standing — healthcare, retail, hairdressing, dental, kitchen work — accelerates symptoms; spending the workday on your feet without breaks doesn't cause the underlying disease but it brings symptoms forward by years.
Where this goes wrong
Treating the surface without scanning underneath. The single most common failure mode is sclerotherapy of visible spider veins or tributary varicosities without first mapping whether a refluxing truncal vein is feeding them. The treated veins come back, often within a year, and the patient concludes the procedure "didn't work" — when really it never addressed the source.
Compression-stocking non-adherence. The stockings only work while they're on. Real-world adherence consistently runs below 50%, and people who buy class-3 stockings (the firmer end) tend to drop off fastest because they're harder to get on. If you're going the conservative route, class 2 with daily wear beats class 3 worn three days a week.
Foam sclerotherapy for large truncal veins. Foam is the right tool for tributaries and the wrong tool for the great saphenous vein at full diameter — 5-year recanalisation rates around 30% in the head-to-head trials make it the least durable option for the main trunk Lawaetz et al. 2017. Useful in the right anatomical niche; over-applied in commercial settings where it's cheaper per session.
Treating during pregnancy. Spends money and procedural risk on disease that may regress on its own. Wait at least three months postpartum, preferably until childbearing is complete.
The vein-clinic upsell. The US private market includes clinics that cosmetically treat C1 spider veins as if they were medical disease, billing insurers and patients aggressively. If your only complaint is the look of fine surface veins and your legs feel fine, that's a cosmetic decision — not a medical one — and the price tag and the marketing should match.
A few neighbouring topics are worth knowing about even though they aren't quite the same disease: pelvic congestion syndrome and vulvar varicosities (refluxing veins in the pelvis rather than the leg, sometimes the hidden source of unexplained leg varicosities), male varicocele (the same valve-failure mechanism in the spermatic veins), post-thrombotic syndrome (the chronic-venous-insufficiency picture caused by an old deep-vein clot rather than primary valve failure), and lymphoedema (a different mechanism of leg swelling that can coexist with venous disease). The cosmetic-only treatment of fine spider veins on healthy legs is its own decision and not what this entry is about.
- — Hours of sitting still let blood pool in your leg veins, worsening the aching and swelling — get up and move every half hour.
- — Jobs that keep you standing still for hours raise the odds of ropy leg veins; sitting-standing rotation beats either extreme.
- — Your calf muscles are the pump that pushes blood back up your legs — a daily walk eases the aching and swelling of varicose veins.
- — A varicocele is essentially varicose veins of the testicle; the underlying valve problem is identical.
Substance + claimed effects
Varicose veins are visibly dilated, tortuous superficial veins of the lower limb (CEAP class C2), almost always caused by reflux at incompetent valves in the great or small saphenous system; chronic venous insufficiency (CVI) is the clinical syndrome that follows from sustained venous hypertension (CEAP C3–C6: edema, hyperpigmentation, eczema, lipodermatosclerosis, healed ulcer, active ulcer) Gloviczki et al. 2023. This entry covers the substance holistically: the cosmetic ropes most people first notice, the underlying valve disease driving them, and the cascade of consequences if reflux is left alone — leg heaviness and aching, daily swelling, sleep-fragmenting cramps and restless legs, skin discoloration and lipodermatosclerosis, venous ulceration, and excess deep-vein thrombosis (DVT) risk. The three established treatments — graduated compression, endovenous thermal or chemical ablation of the refluxing trunk, and sclerotherapy of tributaries — are evaluated for what they actually deliver across these dimensions. Visible cosmetic appearance, day-to-day comfort, and ulcer prevention are the three reader-facing outcomes the dossier centers.
Evidence by addressing question
mechanism
Leg veins return blood against gravity using one-way bicuspid valves and the calf muscle pump. When a valve leaflet fails to coapt — through a primary vein-wall weakness, hormonal vasodilation (pregnancy, oestrogens), prolonged standing, obesity, or a prior DVT — blood refluxes downward and hydrostatic pressure in the column above the next competent valve rises toward arterial levels on standing. The dilated segment stretches the next valve open, propagating reflux distally in a self-perpetuating cycle of venous hypertension. The most frequent site of incompetence is the great saphenous vein, present in roughly 70–80% of cases with reflux and in ~84% of patients presenting with venous ulcers; the saphenofemoral junction is one entry point, but ultrasound mapping shows segmental reflux below the knee in the majority of CEAP C2 limbs rather than a strict top-down cascade. Sustained venous hypertension drives extracellular-matrix remodeling (raised MMP-2, altered collagen I/III ratio), erythrocyte extravasation into the dermis (hemosiderin deposition giving the brown-staining hallmark), and a chronic perivenular inflammatory state that culminates in lipodermatosclerosis and ulceration Caggiati et al. 2008. The mechanism explains why compression — which raises tissue pressure, narrows the vein, and improves valve coaptation — relieves symptoms; and why ablation, which permanently closes the refluxing trunk, breaks the cycle.
evidence
Varicose-vein interventions are among the better-studied vascular procedures, with multiple multicentre RCTs and a 2022/2023 SVS/AVF/AVLS guideline whose recommendations are each anchored to an independent systematic review and meta-analysis Gloviczki et al. 2023. The UK CLASS trial randomised 798 patients with primary varicose veins across 11 centres to endovenous laser ablation (EVLA), ultrasound-guided foam sclerotherapy, or open surgery; at six months, laser and surgery produced better disease-specific quality-of-life scores than foam, and laser had the fewest complications Brittenden et al. 2014. The pre-specified 5-year follow-up confirmed the pattern: Aberdeen Varicose Vein Questionnaire scores remained better with laser or surgery than with foam (adjusted difference for laser vs. foam −2.86, 95% CI −4.49 to −1.22; P<0.001), and laser was the most cost-effective of the three over the catalogue-relevant time horizon Brittenden et al. 2019. The earlier Danish trial of 500 patients (580 legs) randomized to EVLA, radiofrequency ablation (RFA), foam, or stripping showed equivalent technical efficacy among RFA, EVLA, and stripping but a much higher recanalization rate for foam at 5 years (Kaplan–Meier estimate 31.5% for foam vs. ~6% for the others); clinical recurrence and retreatment rates were also higher for foam Rasmussen et al. 2011 Lawaetz et al. 2017. For venous ulcers, the ESCHAR trial in The Lancet showed that adding superficial venous surgery to compression did not change 24-week healing (65% vs. 65%) but cut 12-month recurrence from 28% to 12% (P<0.0001) Barwell et al. 2004, with the 4-year follow-up confirming 31% vs. 56% recurrence and more ulcer-free time in the surgery arm Gohel et al. 2007. The 2018 EVRA NEJM trial extended this to modern endovenous ablation: among 450 patients with active venous ulcers and superficial reflux, early ablation (within 2 weeks) shortened time to healing and lengthened ulcer-free time over the first year (median 306 vs. 278 days; P=0.002) compared with compression alone Gohel et al. 2018. Non-thermal cyanoacrylate closure (VenaSeal) is non-inferior to RFA in the VeClose pivotal RCT at 3 years Morrison et al. 2015. The case for compression stockings as the standalone therapy for established C2 varicose veins is the weakest piece of the evidence base; NICE explicitly recommends against using compression hosiery to treat varicose veins unless interventional treatment is unsuitable NICE CG168 2013. Compression's evidence is strongest for ulcer healing and for reducing ulcer recurrence in CVI (class-2 stockings outperform class-1 for recurrence prevention).
protocol
The pathway recommended by the major guidelines is convergent. Anyone with symptomatic varicose veins, skin changes from CVI, prior superficial thrombophlebitis, a current or healed venous ulcer, or bleeding from a varix is referred to a vascular service for duplex ultrasound to map the refluxing segments NICE CG168 2013. With confirmed truncal reflux, first-line definitive treatment is endovenous thermal ablation (EVLA or RFA) of the refluxing saphenous trunk, performed under local tumescent anaesthesia as an office or day-case procedure; if thermal ablation is unsuitable, ultrasound-guided foam sclerotherapy or cyanoacrylate closure; if neither, traditional high ligation and stripping NICE CG168 2013 Gloviczki et al. 2023. Tributary varicosities are treated concomitantly or in a staged session by phlebectomy or liquid/foam sclerotherapy Gloviczki et al. 2024. Graduated compression stockings (typically 20–30 mmHg or 30–40 mmHg, class 2) are used as adjunctive therapy: post-procedure for 1–2 weeks, lifelong after an ulcer, and as the conservative option for patients who decline or are not candidates for ablation. Lifestyle adjuncts with modest mechanistic support — leg elevation, regular walking (calf-pump activation), weight loss when overweight — are universally recommended but are not stand-alone treatments for established varicose veins. For active venous ulcers, the protocol is multilayer compression bandaging plus early endovenous ablation of the refluxing superficial vein, ideally within 2 weeks of diagnosis Gohel et al. 2018.
contraindications
Treatment is generally deferred during pregnancy; pregnancy-related varicose veins commonly regress in the months after delivery as blood volume, uterine compression on pelvic veins, and progesterone/oestradiol normalize, though severely stretched veins may not fully resolve and risk rises with each subsequent pregnancy. Acute deep vein thrombosis is a contraindication to elective ablation until anticoagulated and stable. Severe peripheral arterial disease (ankle-brachial index <0.5) is a contraindication to firm compression, which can compromise arterial flow; the EVRA trial used an ABI cutoff of ≥0.8 for compression eligibility Gohel et al. 2018. Active superficial thrombophlebitis around the planned ablation segment, known hypercoagulability without anticoagulation, and inability to ambulate post-procedure are relative contraindications. Cyanoacrylate (VenaSeal) is avoided in patients with known acrylate hypersensitivity; foam sclerotherapy carries a small theoretical risk of cerebral gas embolism in patients with a clinically significant right-to-left shunt. Procedural DVT is a recognized complication of all ablation techniques, occurring in roughly 1–3% of cases Gohel et al. 2018.
misconceptions
The dominant misconception in primary care, reinforced by older referral pathways and many UK CCG policies that conflict with NICE, is that varicose veins are a cosmetic problem and that 6 months of compression hosiery should be tried before referral. NICE CG168 explicitly does not endorse this: symptomatic varicose veins or any sign of CVI (skin changes, ulcer, healed ulcer, superficial vein thrombosis) warrants referral to a vascular service, and compression should not be offered as treatment for varicose veins unless interventional treatment is unsuitable NICE CG168 2013. Compliance audits show only ~36% of UK CCGs were fully compliant with this. A second misconception is that varicose veins are predominantly a female problem; the Edinburgh Vein Study found trunk varices in 40% of men vs. 32% of women in a random population sample, with the female excess limited to symptom-reporting and treatment-seeking rather than presence of disease Evans et al. 1999. A third is that recurrence after a "completed" treatment means failure; recurrence is a known feature of all four modalities in the 5-year RCT data (KM estimates 18.7–38.6% across RFA, EVLA, foam, stripping) and reflects the underlying disease's tendency to recruit new refluxing segments Lawaetz et al. 2017.
stakes
The trajectory if reflux is ignored is well documented from the Bonn Vein Study, Edinburgh Vein Study, and the SVS/AVF/AVLS systematic reviews. Roughly 23% of adults have varicose veins by the Bonn cross-section, ~17% have CEAP C3–C6 CVI, and ~0.7% have active or healed venous ulcers Rabe et al. 2003. The progression from C2 (visible varicosities) through C3 (persistent edema), C4 (skin hyperpigmentation and lipodermatosclerosis), C5 (healed ulcer) to C6 (active ulcer) typically unfolds over years to decades but is not inevitable; only a minority of C2 patients reach C6, but those who do face ulcers that are slow to heal, frequently recurrent, and severely quality-of-life impairing. Restless legs and nocturnal cramps are markedly more prevalent in patients with superficial venous reflux and improve after treatment of the underlying reflux (lateral subdermic venous plexus insufficiency was demonstrated in 85% of RLS-symptomatic patients and 92% of those with nocturnal cramps) Pyne et al. 2022. Observational and Mendelian-randomization evidence links varicose veins to a modestly elevated risk of incident DVT (causal OR ~1.1 in MR; 4–8× in confounded observational data) Chang et al. 2018.
payoff
The CLASS 5-year data give the cleanest read on treatment payoff in QoL terms: significant and durable improvement in the Aberdeen Varicose Vein Questionnaire — a composite of pain, swelling, skin changes, and activity interference — at 5 years post-ablation vs. foam Brittenden et al. 2019. The Singapore ASVS registry of cyanoacrylate closure showed Aberdeen score improvements from 17.1 → 4.8 and revised Venous Clinical Severity Score from 5.0 → 1.0 within 3 months. For visible appearance, sclerotherapy reduces or eliminates surface telangiectasias and reticular veins within 4–6 weeks per session; ablated trunks shrink and fade over 3–6 months. For ulcers, EVRA showed faster healing and 28 more ulcer-free days in the first post-intervention year with early ablation; ESCHAR showed 12-month recurrence cut from 28% to 12% with superficial venous surgery added to compression. The size of the felt change is meaningful but modest in healthy C2 cases and substantial in advanced CVI cases — felt-experience prose should anchor on the typical reader (aching, heavy legs at end-of-day; clothing covering visible veins) rather than the ulcer-stage case.
alternatives
The active alternatives to thermal ablation are foam sclerotherapy (cheap, office-based, higher 5-year recanalization rate), cyanoacrylate closure (non-thermal, no tumescent anaesthesia, comparable durability at 3 years per VeClose), mechanochemical ablation (ClariVein), and traditional high ligation and stripping (surgical, durable, more downtime, declining use). For symptomatic patients who decline procedures, daily graduated compression (class 2, 20–30 mmHg) is the conservative path: it relieves heaviness, aching, and edema and is mandatory for ulcer healing, but does not modify the underlying valve disease. Sclerotherapy of cosmetic spider veins (CEAP C1) is a separate, simpler procedure with no impact on the underlying truncal reflux story. Lifestyle measures (calf-pump activation, weight loss, leg elevation) help symptoms but do not reverse established varicose veins. Vasoactive drugs (micronized purified flavonoid fraction) are used in some European countries for symptom control; the evidence is modest.
practicalities
In the UK, NICE-compliant referral and treatment are provided under the NHS for any patient meeting the referral criteria. In the US, endovenous ablation is covered by most insurers when criteria are met (typically documented reflux on duplex, failure of conservative therapy or symptoms interfering with activities). Out-of-pocket and private-market US pricing for endovenous ablation runs roughly $2,000–$5,000 per leg; foam sclerotherapy $300–$600 per session; class-2 compression stockings $50–$120 per pair, replaced every 3–6 months. The procedure itself takes ~30–60 minutes, uses local tumescent anaesthesia, and patients walk out and return to work within 1–3 days. Tributary sclerotherapy or phlebectomy may be needed at the index session or as a staged follow-up. Bruising and tightness along the ablated trunk are expected and resolve within 2–4 weeks. Compression stockings post-ablation are typically worn for 1–2 weeks per institutional preference (the optimal duration is not well established and varies in guidelines).
failure-modes
The recurring failure modes are (1) skipping the duplex ultrasound and treating spider veins cosmetically while the underlying truncal reflux drives recurrence within months; (2) treating the visible varicosities with phlebectomy alone without ablating the saphenous trunk feeding them — guaranteed recurrence; (3) compression-stocking non-adherence, which makes the conservative path largely ineffective (adherence to daily wear in CVI/ulcer cohorts is consistently below 50%); (4) treating during pregnancy when the substrate will regress on its own; and (5) over-treating C1 telangiectasias on women in their 30s as a stand-alone cosmetic issue when truncal reflux is silently progressing. Foam sclerotherapy of large truncal veins has the highest 5-year recanalization (≈31% in Rasmussen et al.) and is best reserved for tributaries or as a salvage option Lawaetz et al. 2017.
audience
Women are more likely to seek treatment and to report symptoms, but population prevalence is roughly equal or higher in men. Pregnant women develop varicose veins in ~15% of pregnancies, mostly second-trimester onset; most regress in the months after delivery and elective treatment is deferred. Older adults (60+) carry most of the C3–C6 burden. Occupational risk factors — prolonged standing or sitting (healthcare workers, retail, hairdressing) — concentrate the disease in specific working populations. Family history is the single largest individual risk factor.
out-of-scope
Pelvic congestion syndrome, vulvar varicosities, and male varicocele share venous-reflux mechanism but are separate clinical entities and would warrant their own entries. Acute DVT, post-thrombotic syndrome, and lymphedema overlap clinically with CVI but are distinct etiologies. The cosmetic-only spider-vein (C1) sclerotherapy case is mentioned but not detailed.
Credibility range
Optimist case
Endovenous ablation is one of the highest-evidence interventions in vascular medicine: four major modalities with multiple multicentre RCTs and a guideline framework where each recommendation rests on an independent systematic review. Walking patients in and out of the office in under an hour with a near-permanent fix for a chronic disease — and with EVRA-grade evidence that the same fix accelerates ulcer healing — places this firmly in the high-value, high-evidence quadrant. Treatment durably improves disease-specific quality of life at 5 years (CLASS) and cuts ulcer recurrence by more than half (ESCHAR). The mechanism is mechanically transparent (closing a refluxing tube), the procedure is mature, and the cost-effectiveness analyses in CLASS-5 and the EVRA economic substudy favor early intervention.
Skeptic case
Most varicose veins in the population are mild and never progress to CVI or ulcer; treating C2 disease is largely a quality-of-life and cosmetic intervention, and the QoL improvements in CLASS, while statistically robust, are modest in absolute Aberdeen-score terms. All ablation modalities have a 15–40% 5-year clinical recurrence rate driven by the underlying disease recruiting new refluxing segments. DVT risk attached to the procedure is small but real (1–3%). Compression stockings have weak evidence as a standalone treatment for varicose veins and high non-adherence in real-world cohorts. Commercial incentives — device manufacturers, vein clinics paid per ablation — drive over-treatment in some markets, including aggressive sclerotherapy of asymptomatic spider veins billed as medical. The Mendelian-randomization causal effect of varicose veins on DVT is small (OR ~1.1), substantially lower than the observational claims. For the median asymptomatic person with C1 or mild C2 disease, the evidence does not compel intervention.
Author's call
This entry lands firmly on the actionable side. The disease has a clear progression risk, treatment is genuinely effective with strong RCT and guideline backing, and the typical reader who reaches this entry has symptoms or visible disease and benefits from understanding the modern pathway (duplex → ablation, not "wear stockings for 6 months and see"). The catch — that recurrence is normal, that compression alone is the wrong choice for established varicose veins, and that the cosmetic-only spider-vein cohort is a different (lower-stakes) problem — is named in the article rather than glossed. Evidence rating is 5; controversy is 1 (the only live disputes are at the modality margin: thermal vs. non-thermal, optimal post-procedure compression duration, cost-effectiveness in lower-severity disease).
Stakeholder + incentive map
- Device manufacturers — Medtronic (ClosureFast RFA, VenaSeal cyanoacrylate), Angiodynamics, Boston Scientific. Commercial push for newer non-thermal modalities; sponsors of pivotal RCTs including VeClose. Aligned with intervention.
- Vascular societies — SVS, AVF, AVLS, Society of Interventional Radiology. Issued the 2022/2023 guideline framework; promote referral to dedicated vascular services. Aligned with intervention.
- Vein clinics — per-procedure-paid private practices in the US. Commercial incentive to over-treat C1 cosmetic disease and to bill insurers for symptomatic justification. Largest source of bias.
- NHS commissioners / UK CCGs — cost-containment incentive to require trials of compression before referring. Documented non-compliance with NICE CG168 (~64% of CCGs deviating).
- Compression-hosiery manufacturers — Sigvaris, Mediven, Jobst. Aligned with conservative-first pathway.
- Primary care / GPs — historically taught varicose veins are cosmetic. Slow update of referral practice.
- Patients themselves — divided between cosmetic-only concern (younger women with telangiectasias) and quality-of-life-driven referral (older patients with heaviness, swelling, skin changes).
Population variability
- Sex. Women are more symptomatic and more treatment-seeking; population prevalence is comparable or slightly higher in men Evans et al. 1999. Pregnancy effects are female-only.
- Age. Prevalence and severity rise steeply with age; most CEAP C4–C6 disease occurs after 60.
- Family history. Single strongest individual risk factor — relative risk ~6× when both parents affected. Polygenic susceptibility (HFE, FOXC2, others) maps in GWAS.
- Body habitus. Obesity increases CVI risk via intra-abdominal pressure transmission; modest BMI reduction can reduce symptoms.
- Occupation. Prolonged standing/sitting (healthcare workers, retail) accelerates symptomatic disease.
- Pregnancy parity. Risk rises with each pregnancy; ~65% prevalence in women with 5+ pregnancies vs. 20% in nulliparous women over 40.
- Ethnicity/geography. Higher reported prevalence in Western/industrialized populations, though this may partly reflect ascertainment.
Knowledge gaps
- Optimal post-procedure compression duration is not established — guidelines range from 0 to 4 weeks with little RCT support for any specific protocol.
- Long-term (10+ year) comparative durability of cyanoacrylate vs. thermal ablation is unknown; VeClose 5-year follow-up was underpowered due to attrition.
- Whether prophylactic ablation in asymptomatic but documented reflux prevents progression to CVI/ulcer is unstudied.
- The mechanism linking superficial venous reflux to restless legs syndrome is incompletely characterized; the LSVP work is observational and single-center.
- Causal effect size of varicose veins on incident DVT — Mendelian randomization suggests it is much smaller than observational estimates, but the question is not closed.
- Whether vasoactive medications (MPFF, sulodexide) meaningfully alter long-term disease trajectory in adjunctive use is uncertain.
Scope and brief. Covered everything the topic brief named: visible varicose veins, underlying CVI, heaviness/swelling, skin changes, ulceration risk, compression, endovenous ablation, sclerotherapy. Held to a single entry as instructed — substance plus all meaningful consequences — even though CVI and varicose veins are sometimes split clinically.
Action choice — decide rather than do or respond. The reader's primary action is to weigh a real tradeoff with a vascular service: stockings forever vs. procedure now vs. wait. respond would have fit if this were ulcer-only; do would have understated the procedural decision. decide matches the SVS/AVF/AVLS and NICE pathway framing.
Cadence — as-needed. Trigger-based: symptoms emerge, the reader acts. Compression is daily but conditional on choice; the underlying decision is not a recurring habit.
Rating call: longevity at 1. Tempted to score 0 — venous disease rarely kills — but the DVT linkage (small but causal per Mendelian randomization) and the modest infection-related mortality from chronic ulcers earn a marginal but non-zero longevity score. Did not push to 2 because the absolute mortality contribution is small.
Rating call: beauty_direct and beauty_cumulative both at 3. Direct cosmetic effect of treatment is real and visible-to-others within weeks (3, not 4, because it's not days). Cumulative cosmetic effect is the prevented-trajectory framing — stopping the brown ankle staining and lipodermatosclerosis from accumulating — a real long-term aesthetic improvement, not transformative.
Rating call: sleep and mood at 2. Sleep gets 2 on the strength of the Pyne 2022 LSVP/RLS work and consistent practitioner reports of cramp/RLS improvement after ablation; could have been 3 in the symptomatic-CVI subset but 2 averages across the typical reader. Mood at 2 for similar reasoning — meaningful in CVI/ulcer cases, modest in C2-only.
Contraindications. Marked pregnancy only. Considered blood-thinners but the modern evidence (including EVRA) supports performing ablation on anticoagulated patients in most cases, so it would mislead more than warn.
Excluded, with reason. Pelvic congestion, vulvar varicosities, varicocele, and post-thrombotic syndrome were flagged as adjacent in out-of-scope but not detailed — each warrants its own entry. Did not get into specifics of mechanochemical ablation (ClariVein) or sodium tetradecyl sulphate vs. polidocanol as sclerosants — clinician-level decisions the reader doesn't make.
Editorial choice: headingless mechanism. The opening mechanism section runs without an H2 so the dek flows directly into the first content block; the first visible heading lands on evidence. All later addressing sections carry H2s for scannability given the article's length.
Future-link candidates. deep-vein-thrombosis, compression-stockings, venous-leg-ulcer, restless-legs-syndrome, lymphoedema, pelvic-congestion-syndrome.
Separate-entry candidates. Restless legs syndrome — strong enough literature base and clinical importance to warrant its own entry; the venous-reflux mechanism is one of several causal stories and deserves more depth than this entry could give. Pelvic congestion syndrome — a real and under-diagnosed cause of leg varicose veins arising from pelvic reflux; needs its own pathway.
Varicose Veins
Multiple multicentre RCTs (CLASS, Rasmussen/Lawaetz, EVRA, ESCHAR, VeClose) with 5-year follow-up data, all converging on the same pathway. Guideline-backed by NICE CG168 (2013) and the SVS/AVF/AVLS 2022/2023 framework whose recommendations each rest on independent systematic reviews.
Treatment itself is a single ~30–60 minute office procedure with 1–3 days recovery. Conservative path requires daily wear of class-2 compression stockings — a minor but persistent lifestyle adjustment; lifelong post-ulcer.
Endovenous ablation and sclerotherapy of refluxing trunks and tributaries visibly fade or eliminate ropy varicosities and telangiectasias within weeks to months; CLASS and ASVS registry data show large reductions in Aberdeen Varicose Vein Questionnaire (Brittenden 2019, Singapore ASVS 3-month follow-up).
Untreated venous hypertension drives haemosiderin staining, lipodermatosclerosis, and ulcer-scar deformity (CEAP C4–C5); treating the underlying reflux prevents or arrests this skin-change trajectory (Caggiati 2008, Gloviczki 2023a).
Heaviness, aching, edema, night cramps, and itching are common and improve after ablation; CLASS 5-year disease-specific QoL improvements were significantly better with EVLA or surgery than with foam (Brittenden 2019).
Endovenous ablation runs roughly $2,000–$5,000 per leg out of pocket in US private markets (covered by most insurers and the NHS when criteria are met); ongoing compression stockings ~$100–$200/year; staged sclerotherapy adds $300–$600 per session.
Reduction in end-of-day leg heaviness and the venous-claudication component of leg fatigue produces a real but modest daily-energy effect after successful ablation; magnitude is bounded by the symptom's contribution to fatigue not being dominant.
Restless-legs symptoms and nocturnal cramps are markedly more prevalent in patients with superficial venous reflux (LSVP abnormal in 85% of RLS-symptomatic and 92% of cramp-symptomatic patients) and improve after treatment of the underlying veins (Pyne 2022).
Disease-specific and generic QoL improve after ablation in CLASS and EVRA; chronic venous ulcer patients show substantial mood and functional gains with ulcer healing (Gohel 2018). Magnitude is small in mild C2 disease and meaningful in symptomatic CVI.
Venous disease itself is rarely fatal, but varicose veins are associated with a modestly elevated incident DVT risk (causal OR ~1.1 by Mendelian randomization; larger in observational cohorts including Chang 2018), and chronic ulcers carry small but real infection-related mortality.